R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial
Authors
Keywords
-
Journal
Lancet Haematology
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-11-01
DOI
10.1016/s2352-3026(23)00279-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain
- (2022) Josep-Maria Ribera et al. LEUKEMIA & LYMPHOMA
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
- (2022) Rita Alaggio et al. LEUKEMIA
- Burkitt’s Lymphoma
- (2022) Mark Roschewski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Burkitt Lymphoma International Prognostic Index
- (2021) Adam J. Olszewski et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma
- (2020) Mark Roschewski et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial
- (2016) Vincent Ribrag et al. LANCET
- AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma
- (2015) A. Noy et al. BLOOD
- Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial
- (2014) D. Hoelzer et al. BLOOD
- Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002
- (2014) David A. Rizzieri et al. BRITISH JOURNAL OF HAEMATOLOGY
- Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
- (2014) Sally F. Barrington et al. JOURNAL OF CLINICAL ONCOLOGY
- A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma
- (2013) A. M. Evens et al. ANNALS OF ONCOLOGY
- Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases
- (2013) L. J. Costa et al. BLOOD
- Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status
- (2013) Josep-Maria Ribera et al. CANCER
- High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program
- (2013) T. Intermesoli et al. HAEMATOLOGICA
- Low-Intensity Therapy in Adults with Burkitt's Lymphoma
- (2013) Kieron Dunleavy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis
- (2011) J. A. Barnes et al. ANNALS OF ONCOLOGY
- RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B-cell lymphoma
- (2011) Gaetano Corazzelli et al. BRITISH JOURNAL OF HAEMATOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started